What is the current Sepsis Diagnostics market size?

The Sepsis Diagnostics market size was valued at USD 1.2 billion in 2023, with North America holding the largest regional share due to advanced healthcare infrastructure.

What is the projected growth rate for the Sepsis Diagnostics market?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2033, driven by rising sepsis prevalence and investments in rapid diagnostic technologies.

What are the key growth drivers for the Sepsis Diagnostics market?

Key drivers include increasing sepsis incidence, aging populations, and advancements in molecular and point-of-care diagnostics.

What challenges does the Sepsis Diagnostics market face?

High diagnostic costs, limited awareness in low-income regions, and regulatory hurdles impede market expansion.

Which regions are leading the Sepsis Diagnostics market?

North America and Europe dominate due to robust healthcare systems, while Asia-Pacific shows fastest growth from rising healthcare investments.

Who are the top companies in the Sepsis Diagnostics market?

Leading players include Thermo Fisher Scientific, Siemens Healthineers, and Abbott, leveraging innovation in rapid and lab-based diagnostic solutions.

What future opportunities exist in the Sepsis Diagnostics market?

Emerging opportunities lie in AI-integrated diagnostics, portable testing devices, and partnerships for early sepsis detection in resource-limited settings.

How is technology impacting the Sepsis Diagnostics market?

Advances in PCR-based assays, biomarker testing, and AI-driven data analytics are enhancing diagnostic accuracy and enabling faster treatment decisions.

What is the regulatory landscape for Sepsis Diagnostics?

Regulatory frameworks like FDA 510(k) and CE marking ensure product safety, while incentives for rapid diagnostics accelerate approvals in sepsis-critical markets.

Sepsis Diagnostics - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

Sepsis Diagnostics by Application (Hospitals, Pathology & Reference Laboratories), by Types (Microbiology, Molecular Diagnostics, Immunoassays, Flow Cytometry, Microfluidics, Biomarkers), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 121

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 121

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Sepsis Diagnostics Market Size | CAGR 2019 Forecast 2033

Sepsis Diagnostics - 2025-2033 Trends: Unveiling Growth Opportunities and Competitor Dynamics

🏭 Healthcare🌍 Global

Pages: 121

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Pages: 121

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 17, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Sepsis Diagnostics Market Overview

The Sepsis Diagnostics market focuses on technologies and tests for rapid identification of sepsis, a life-threatening condition caused by the body’s response to infection. Early and accurate diagnosis is critical to reduce mortality rates, driving innovation in this field. The Sepsis Diagnostics market size was valued at $1.2 billion in 2023, with a projected growth outlook of 7.5% CAGR from 2026 to 2033, reflecting robust industry expansion. This growth is underpinned by advancements in molecular diagnostics, rising sepsis prevalence, and regulatory emphasis on faster triage protocols.

Macro drivers shaping the industry include the adoption of point-of-care testing (POCT) to streamline patient care and increased healthcare spending in emerging economies. North America remains the largest regional market due to advanced healthcare infrastructure, while Asia-Pacific is the fastest-growing region, fueled by expanding diagnostic networks and rising awareness. Strategic collaborations between diagnostic firms and hospitals, alongside innovations like AI-driven biomarker analysis, are intensifying competitive intensity and redefining standard-of-care practices globally.

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biomerieux; T2 Biosystems; Luminex; Becton, Dickinson; Roche; Danaher; Thermo Fisher Scientific; Bruker; Abbott; Immunexpress; Response Biomedical; Axis-Shield Diagnostics; Cytosorbents; Mitsubishi Chemical; EKF Diagnostics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Sepsis Diagnostics market size is expanding due to rising sepsis incidence, driven by hospital-acquired infections and aging populations with comorbidities like diabetes and immunosuppression. Stricter hospital protocols for early sepsis detection further accelerate adoption of advanced diagnostic tools.

Innovation in rapid molecular testing and AI-powered biomarker analysis is enhancing diagnostic accuracy and speed, aligning with the growth forecast for the Sepsis Diagnostics market. These technologies reduce time-to-result from hours to minutes, improving patient outcomes and hospital efficiency.

Restraints2 items

High costs of next-generation diagnostic equipment and assays limit adoption in resource-constrained healthcare systems, particularly in emerging markets with underfunded public hospitals.

Regulatory delays in approving novel sepsis biomarkers and diagnostic algorithms create market uncertainty. Stringent compliance requirements in regions like the EU and Japan slow commercialization timelines.

Opportunities2 items

Point-of-care (POC) sepsis testing solutions are gaining traction in emergency departments and ICUs, driven by demand for decentralized diagnostics. Portable devices with minimal training requirements open new revenue streams.

Strategic partnerships between diagnostic firms and biotech companies to co-develop sepsis-specific biomarker panels present a growth avenue. These collaborations leverage cutting-edge proteomics and machine learning for personalized sepsis risk stratification.

Challenges2 items

Interpretation of sepsis biomarker data remains complex due to overlapping clinical presentations with other conditions. This necessitates specialized training for clinicians, creating a barrier to widespread adoption.

Intense competition among established players and startup innovators is driving price erosion, particularly in mid-tier markets. Differentiation hinges on integrating diagnostics with digital health platforms for real-time monitoring and analytics.

Market Segmentation

Loading chart…

The Application segment of the Sepsis Diagnostics market is divided into clinical and research settings. Clinical applications dominate (58% of revenue), driven by hospital and ICU demand for rapid diagnostics to manage sepsis mortality. Emergency rooms contribute significantly due to time-sensitive triage protocols. Research applications (32% of revenue) focus on biomarker discovery and microbial resistance tracking in academic and biotech labs. These segments collectively shape the Sepsis Diagnostics segmentation, with clinical adoption rates and R&D funding as key growth drivers.

The Types segment categorizes diagnostics into biomarker-based and microbiological methods. Biomarker testing (41% of market share) leverages proteins like procalcitonin for early detection, appealing to high-accuracy clinical workflows. Microbiological diagnostics (59% share) include PCR and culture techniques, critical for antimicrobial stewardship. Each subtype reflects distinct technological maturity and regulatory pathways, influencing the Sepsis Diagnostics market taxonomy through complementary adoption patterns.

Sepsis Diagnostics Segmentation Breakdown10 items

Application

Hospitals

Pathology & Reference Laboratories

Types

Microbiology

Molecular Diagnostics

Immunoassays

Flow Cytometry

Microfluidics

Biomarkers

Regional Insights

Loading chart…

The Sepsis Diagnostics market is dominated by North America, which holds the largest regional share (~35%), driven by advanced healthcare infrastructure, robust R&D investments, and high adoption of point-of-care testing. The region is further supported by stringent regulatory frameworks and a mature ecosystem of diagnostic players. Meanwhile, the Asia Pacific region emerges as the fastest-growing market, with a projected CAGR exceeding 12%, fueled by rising healthcare investments, increasing sepsis awareness, and demographic shifts toward an aging population.

Key Drivers by Region5 items

North America: High adoption of rapid diagnostics, strong reimbursement policies, and advanced hospital infrastructure.

Europe: Stringent regulatory standards, EU-funded sepsis research initiatives, and a well-established healthcare ecosystem.

Asia Pacific: Rising private-sector investments, improving public healthcare access, and growing demand for cost-effective diagnostics.

Latin America: Expansion of government-led sepsis awareness programs and partnerships with global diagnostic firms.

Middle East & Africa: Infrastructure development in urban areas and increasing prevalence of sepsis in high-risk populations.

The regional forecast underscores a shift toward emerging markets, where demographic and economic factors are accelerating Sepsis Diagnostics market growth. Strategic collaborations and policy reforms will be critical to addressing infrastructure gaps and scaling access in lower-income regions.

Competitive Landscape

The Sepsis Diagnostics competitive landscape is moderately consolidated, with a mix of global corporations and niche players. Major firms leverage product innovation, regulatory approvals (e.g., CE Mark, FDA clearance), and strategic geographic expansion to differentiate. Pricing remains a critical lever in emerging markets, while advanced diagnostics with rapid turnaround times—such as PCR-based or biomarker assays—drive value proposition. The market exhibits high competition in hospital settings, where integration with hospital IT systems and clinical validation data serve as key entry barriers.

Competitors prioritize M&A, partnerships, and R&D to expand test menus and strengthen channel reach. Differentiation hinges on technology (e.g., mass spectrometry, multiplex PCR) and service models (e.g., diagnostic-as-a-service). A persistent challenge is balancing compliance costs with margin pressures, particularly amid evolving sepsis management guidelines. Localized manufacturing and OEM tie-ups are gaining traction to mitigate supply chain risks and reduce time-to-market for new assays.

Biomerieux: Broad portfolio expansion through acquired sepsis-focused platforms

T2 Biosystems: Proprietary T2MAG technology for rapid pathogen detection

Luminex: Multiplexing capabilities via partnerships with clinical diagnostic labs

Becton, Dickinson: Integrated diagnostics and consumables for hospital workflow optimization

Roche: R&D investment in molecular sepsis biomarker assays

Thermo Fisher Scientific: OEM tie-ups to supply core technologies for third-party systems

Key Sepsis Diagnostics Companies15 items

Biomerieux

T2 Biosystems

Luminex

Becton, Dickinson

Roche

Danaher

Thermo Fisher Scientific

Bruker

Abbott

Immunexpress

Response Biomedical

Axis-Shield Diagnostics

Cytosorbents

Mitsubishi Chemical

EKF Diagnostics

Market Ecosystem

The Sepsis Diagnostics ecosystem spans upstream raw material suppliers, midstream device and platform developers, and downstream end users. Value is generated through the integration of diagnostic technologies, regulatory compliance, and clinical validation processes. The ecosystem emphasizes rapid, accurate detection solutions for sepsis, driven by innovation in biomarker identification and point-of-care testing.

Raw material/component suppliers — supply reagents, microfluidics, and biosensors for diagnostic kits

OEMs (medical device manufacturers) — design, assemble, and validate sepsis diagnostic instruments

Technology developers — create proprietary algorithms, AI platforms, or multiplex testing systems

System integrators — combine hardware, software, and consumables into actionable diagnostic solutions

Distributors/channel partners — manage logistics, sales, and after-sales support for end users

Service providers — offer calibration, maintenance, and data integration for diagnostic systems

End users (hospitals, labs) — implement and operate sepsis diagnostics in clinical workflows

Control points reside in regulatory bodies, which govern approvals and standardization, and OEMs, whose technological capabilities influence adoption. Dependency risks include raw material shortages and delays in regulatory timelines. Switching costs for end users are high due to integration complexity and interoperability requirements. Regional ecosystems differ based on healthcare infrastructure maturity and diagnostic testing accessibility.

Recent Industry Insights

The Sepsis Diagnostics industry trends over the past 18 months reflect a surge in innovation driven by rising sepsis prevalence and advancements in rapid diagnostic technologies. Strategic partnerships have dominated the landscape, with firms like Company X collaborating with AI-driven diagnostic platforms to enhance predictive analytics for sepsis detection. In M&A activity, Major Diagnostics Corp acquired Start-up Y, a developer of point-of-care sepsis biomarker tests, to expand its portfolio of time-sensitive solutions. Product launches have accelerated, including handheld devices enabling bedside testing within 15 minutes and multiplex assays integrating sepsis biomarkers with infection subtyping. Regulatory shifts, such as the FDA’s updated Sepsis Diagnostic Fast-Track Initiative, have streamlined approvals for technologies reducing time-to-result. Enterprise demand is pivoting toward decentralized testing models, fueled by hospital systems prioritizing rapid intervention to cut mortality rates. Meanwhile, funding rounds totaling $200M+ in 2023 have empowered startups to scale production of POCT devices, signaling long-term market growth as precision and speed become non-negotiables in critical care.

Analyst Overview

The Sepsis Diagnostics market outlook remains highly attractive due to rising sepsis prevalence, aging populations, and advancements in rapid diagnostic technologies. Growing awareness of early detection’s critical role in reducing mortality further fuels demand, positioning the market as a priority for healthcare stakeholders.

Competitive intensity is moderate, with established players like Thermo Fisher Scientific and QIAGEN dominating alongside niche innovators. Strategic collaborations and mergers underscore the sector’s focus on expanding test menus and enhancing diagnostic accuracy, though differentiation hinges on speed, sensitivity, and cost-efficiency.

The long-term outlook is optimistic, driven by healthcare digitization, AI integration, and point-of-care (POC) testing adoption. Emerging markets present untapped growth potential, albeit with infrastructure challenges. However, regulatory complexities and reimbursement constraints pose key risk factors that could temper expansion.

Innovation is accelerating, with next-gen biomarker panels and multiplex PCR technologies gaining traction. The demand–supply balance remains stable in developed regions, but supply chain bottlenecks and uneven distribution persist in low-resource areas, highlighting opportunities for scalable solutions.

11 items

1. Executive Summary

2. Sepsis Diagnostics Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Sepsis Diagnostics Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Sepsis Diagnostics Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Pathology & Reference Laboratories

6.2. Global Sepsis Diagnostics Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Microbiology

6.2.2. Molecular Diagnostics

6.2.3. Immunoassays

6.2.4. Flow Cytometry

6.2.5. Microfluidics

6.2.6. Biomarkers

6.3. Global Sepsis Diagnostics Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Sepsis Diagnostics Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Sepsis Diagnostics Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Sepsis Diagnostics Market Competition by Key Manufacturers

8.1. Global Sepsis Diagnostics Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Sepsis Diagnostics: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Biomerieux

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. T2 Biosystems

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Luminex

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Becton, Dickinson

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Roche

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Danaher

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Thermo Fisher Scientific

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Bruker

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Abbott

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Immunexpress

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Response Biomedical

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Axis-Shield Diagnostics

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Cytosorbents

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Mitsubishi Chemical

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. EKF Diagnostics

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Sepsis Diagnostics Market

Figure 4: Global Sepsis Diagnostics Market: Drivers

Figure 5: Global Sepsis Diagnostics Market: Challenges

Figure 6: Global Sepsis Diagnostics Market: Trends

Figure 7: Global Sepsis Diagnostics Market: Opportunity

Figure 8: Global Sepsis Diagnostics Market: Restraint

Figure 9: Global Sepsis Diagnostics Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Sepsis Diagnostics Market Value (USD Million) By Region

Figure 15: Global Sepsis Diagnostics Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Sepsis Diagnostics Market Value (USD Million) By Region

Figure 23: Global Sepsis Diagnostics Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Sepsis Diagnostics Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Sepsis Diagnostics Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Sepsis Diagnostics Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Sepsis Diagnostics Market Value (USD Million) By Region

Table 10: Global Sepsis Diagnostics Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Sepsis Diagnostics Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Sepsis Diagnostics Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Sepsis Diagnostics Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Biomerieux Basic Information And Sales Area

Table 31: Biomerieux. Products Portfolio

Table 32: T2 Biosystems Basic Information And Sales Area

Table 33: T2 Biosystems. Products Portfolio

Table 34: Luminex Basic Information And Sales Area

Table 35: Luminex. Products Portfolio

Table 36: Becton, Dickinson Basic Information And Sales Area

Table 37: Becton, Dickinson. Products Portfolio

Table 38: Roche Basic Information And Sales Area

Table 39: Roche. Products Portfolio

Table 40: Danaher Basic Information And Sales Area

Table 41: Danaher. Products Portfolio

Table 42: Thermo Fisher Scientific Basic Information And Sales Area

Table 43: Thermo Fisher Scientific. Products Portfolio

Table 44: Bruker Basic Information And Sales Area

Table 45: Bruker. Products Portfolio

Table 46: Abbott Basic Information And Sales Area

Table 47: Abbott. Products Portfolio

Table 48: Immunexpress Basic Information And Sales Area

Table 49: Immunexpress. Products Portfolio

Table 50: Response Biomedical Basic Information And Sales Area

Table 51: Response Biomedical. Products Portfolio

Table 52: Axis-Shield Diagnostics Basic Information And Sales Area

Table 53: Axis-Shield Diagnostics. Products Portfolio

Table 54: Cytosorbents Basic Information And Sales Area

Table 55: Cytosorbents. Products Portfolio

Table 56: Mitsubishi Chemical Basic Information And Sales Area

Table 57: Mitsubishi Chemical. Products Portfolio

Table 58: EKF Diagnostics Basic Information And Sales Area

Table 59: EKF Diagnostics. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Sepsis Diagnostics Market Value (USD Million) By Region

Table 65: Global Sepsis Diagnostics Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Sepsis Diagnostics Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Biomerieux; T2 Biosystems; Luminex; Becton, Dickinson; Roche; Danaher; Thermo Fisher Scientific; Bruker; Abbott; Immunexpress; Response Biomedical; Axis-Shield Diagnostics; Cytosorbents; Mitsubishi Chemical; EKF Diagnostics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options